Top Page
Invex Therapeutics Ltd.
(Sydney:IXC)
Invex Therapeutics Ltd. (IXC) vs. iShares MSCI Australia ETF (EWA)
Invex Therapeutics Ltd. Business Overview & Revenue Model
Invex Therapeutics Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 229.08K | 229.08K | 1.21M | 459.08K | 182.25K | 0.00 |
| Gross Profit | 229.08K | 229.08K | 1.21M | 459.08K | 182.25K | 0.00 |
| EBITDA | -356.54K | 0.00 | -720.00K | -8.21M | -4.14M | -2.28M |
| Net Income | -477.33K | -476.87K | -1.64M | -7.75M | -3.95M | -2.28M |
Balance Sheet | ||||||
| Total Assets | 5.47M | 5.47M | 6.12M | 22.80M | 29.49M | 32.74M |
| Cash, Cash Equivalents and Short-Term Investments | 5.38M | 5.38M | 6.03M | 22.47M | 29.34M | 32.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 220.59K | 220.59K | 431.63K | 1.57M | 1.00M | 658.61K |
| Stockholders Equity | 5.25M | 5.25M | 5.69M | 21.23M | 28.48M | 32.08M |
Cash Flow | ||||||
| Free Cash Flow | -652.57K | -652.57K | -2.44M | -6.87M | -3.38M | -1.68M |
| Operating Cash Flow | -652.57K | -652.57K | -2.44M | -6.87M | -3.38M | -1.68M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 0.00 | 0.00 | -14.00M | 0.00 | 0.00 | 8.09M |
Invex Therapeutics Ltd. Technical Analysis
Invex Therapeutics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$203.87M | -7.77 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$9.02M | -18.25 | -8.72% | ― | ― | 71.10% | |
45 Neutral | AU$11.05M | ― | -469.35% | ― | ― | 46.28% | |
41 Neutral | AU$87.00M | -5.26 | -42.68% | ― | ― | 63.46% | |
38 Underperform | AU$54.55M | -7.60 | -159.86% | ― | 110.44% | 35.90% | |
37 Underperform | AU$13.77M | -1.61 | -628.72% | ― | ― | 31.87% |
Invex Therapeutics Ltd. Corporate Events
Invex Therapeutics Ltd has announced a deferral of its 2025 Annual General Meeting (AGM) to 28 February 2026, following an extension granted by the Australian Securities and Investments Commission. This decision comes after a series of board changes, including the resignation of two directors and the appointment of new non-executive directors. The company plans to issue a new notice of meeting to address the re-election of current directors and the election of new board members, reflecting its ongoing governance adjustments.
Invex Therapeutics Ltd. has announced the appointment of Mr. Simon Llewellyn Owen as a new director, effective November 10, 2025. The announcement indicates that Mr. Owen currently holds no relevant interests in securities, which may suggest a fresh perspective in his role, potentially impacting the company’s strategic direction and stakeholder interests.
Invex Therapeutics Ltd has announced the lifting of its trading suspension on the ASX following the release of information regarding new board and officer appointments. This development is expected to enhance the company’s governance and potentially influence its strategic direction, impacting stakeholders and market perception positively.
Invex Therapeutics Limited announced significant changes in its board and executive team, appointing Simon Owen and Professor Warren Harding AM as non-executive directors. These appointments align with the company’s compliance with corporate regulations and bring extensive experience in corporate governance, strategic planning, and innovation. Additionally, Carla Healy and Tim Slate have been appointed as joint company secretaries, enhancing the company’s communication and compliance capabilities. The company also announced a change in its registered office address to Perth, WA.
Invex Therapeutics Ltd announced the cessation of Dr. Thomas Duthy as a director, effective November 7, 2025. Dr. Duthy held 285,661 ordinary shares through Emmirato Pty Ltd, where he serves as a director and shareholder. This change in directorship may impact the company’s strategic direction and investor relations, as leadership transitions can influence stakeholder confidence and operational focus.
Invex Therapeutics Ltd announced the resignation of its Chairman, Mr. David McAuliffe, Executive Director, Dr. Thomas Duthy, and Company Secretary and CFO, Ms. Narelle Warren, with immediate effect. These resignations led to the cancellation of a requisitioned general meeting that was initially scheduled to address the removal of these directors. This development may impact the company’s governance and strategic direction, as well as its relationship with stakeholders, particularly the requisitioning shareholder, Celtic Capital Pte Ltd.
Invex Therapeutics Ltd has been suspended from quotation on the ASX due to non-compliance with the Corporations Act 2001, specifically for not having sufficient directors. The suspension will remain until the company meets the ASX’s listing rules, impacting its market operations and requiring resolution to regain trading status.
Invex Therapeutics Ltd announced new findings from its collaboration with Tessara Therapeutics, showing that Exenatide significantly reduces neurofilament light chain expression, a marker of neuronal damage, in Alzheimer’s Disease models. This suggests Exenatide’s potential in mitigating early neurodegenerative processes and enhancing its therapeutic value in treating Alzheimer’s Disease, despite uncertainties regarding the continuation of the Tessara collaboration due to potential board changes.
Invex Therapeutics Ltd has announced that its 2025 Annual General Meeting will be held virtually on November 25, 2025. Shareholders can access the Notice of Meeting and related materials online, and voting will be conducted via proxy. The virtual format and online access to materials reflect the company’s adaptation to modern communication methods, potentially increasing accessibility and engagement among shareholders.